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Gene-environment interactions 
due to quantile-specific heritability 
of triglyceride and VLDL 
concentrations
paul t. Williams
“Quantile-dependent expressivity” is a dependence of genetic effects on whether the phenotype (e.g., 
triglycerides) is high or low relative to its distribution in the population. Quantile-specific offspring-
parent regression slopes (βop) were estimated by quantile regression for 6227 offspring-parent 
pairs. Quantile-specific heritability (h2), estimated by 2βop/(1 + rspouse), decreased 0.0047 ± 0.0007 
(P = 2.9 × 10−14) for each one-percent decrement in fasting triglyceride concentrations, i.e., h2 ± Se 
were: 0.428 ± 0.059, 0.230 ± 0.030, 0.111 ± 0.015, 0.050 ± 0.016, and 0.033 ± 0.010 at the 90th, 
75th, 50th, 25th, and 10th percentiles of the triglyceride distribution, respectively. Consistent with 
quantile-dependent expressivity, 11 drug studies report smaller genotype differences at lower (post-
treatment) than higher (pre-treatment) triglyceride concentrations. This meant genotype-specific 
triglyceride changes could not move in parallel when triglycerides were decreased pharmacologically, 
so that subtracting pre-treatment from post-treatment triglyceride levels necessarily created a greater 
triglyceride decrease for the genotype with a higher pre-treatment value (purported precision-medicine 
genetic markers). In addition, sixty-five purported gene-environment interactions were found to be 
potentially attributable to triglyceride’s quantile-dependent expressivity, including gene-adiposity 
(APOA5, APOB, APOE, GCKR, IRS-1, LPL, MTHFR, PCSK9, PNPLA3, PPARγ2), gene-exercise (APOA1, 
APOA2, LPL), gene-diet (APOA5, APOE, INSIG2, LPL, MYB, NXPH1, PER2, TNFA), gene-alcohol 
(ALDH2, APOA5, APOC3, CETP, LPL), gene-smoking (APOC3, CYBA, LPL, USF1), gene-pregnancy (LPL), 
and gene-insulin resistance interactions (APOE, LPL).
Obesity, physical inactivity, high-carbohydrate diets, alcohol intake, smoking, pregnancy, and type 2 diabetes 
mellitus (T2DM) all increase triglyceride concentrations1. The magnitude of the increase varies substantially 
across individuals, which has been attributed in part to gene-environment interactions.
An alternative to gene-environment interaction is quantile-dependent expressivity, i.e., a dependence of 
genetic effects upon whether the phenotype (e.g., triglycerides) is high or low relative to its distribution in the 
population2. Specifically, different genetic effects can be obtained by selecting subjects for characteristics that 
distinguish high vs. low portions of the triglyceride distribution. We have shown that the effect size of a 31-SNP 
genetic risk score (GRSTG) increased significantly with increasing percentile of the triglycerides distribution2. 
Specifically, the effect of the GRSTG on triglyceride concentrations was 3.3-fold greater at the 90th percentile of 
the triglyceride distribution than at its 10th percentile. Within individuals, we have also shown that the genetic 
effect size for polymorphisms associated with ABCA1, APOA1, APOA2, APOA4, APOA5, APOB, APOC3, APOE, 
CETP, FABP2, FATP6, GALNT2, GCKR, HL, IL1b, LEPR, LOX-1, LPL, MC4R, MTP, NPY, SORT1, TNFA, TCF7L2, 
and TM6SF2 became significantly greater as the average triglyceride concentrations over all genotypes increased 
during postprandial lipemia3. Quantile-dependent expressivity has also been demonstrated for total cholesterol2, 
high- and low-density lipoprotein cholesterol2, body mass index2, and coffee consumption4.
Only about 11% of the triglyceride variance is currently explained by the 36 single nucleotide polymorphisms 
(SNP) showing genome-wide significance for fasting plasma triglyceride concentrations5,6. In contrast, heritabil-
ity (h2) calculated from monozygotic twins raised together and apart suggest that additive genetic effects account 
for 54% to 65% of the triglyceride variance7. Verification of quantile-dependent expressivity was therefore sought 
Lawrence Berkeley National Laboratory, Molecular Biophysics & Integrated Bioimaging Division 1 Cyclotron Road, 
Berkeley, CA, 94720, USA. email: ptwilliams@lbl.gov
open
2Scientific RepoRtS |         (2020) 10:4486  | https://doi.org/10.1038/s41598-020-60965-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
using a more inclusive genetic measure in a larger population. To this end, we applied quantile regression8,9 to sib-
ships and offspring-parent pairs from the Framingham Study10,11 to estimate heritability in the narrow sense (h212) 
at different quantile of the plasma triglyceride and very-low-density lipoprotein (VLDL) cholesterol distributions. 
Its importance is illustrated in fourteen published reports of drug or other treatment by genotypes interactions 
that were originally interpreted from a precision-medicine perspective13–25, and sixty-five other published exam-
ples originally attributed to biological interactions between genes and environment26–80, which might be more 
simply ascribed to quantile-dependent expressivity.
Methods
The Framingham Study data were obtained from the National Institutes of Health FRAMCOHORT, GEN3, 
FRAMOFFSPRING Research Materials from the NHLBI Biologic Specimen and Data Repository Information 
Coordinating Center. The Offspring Cohort consisted of 5,124 adult children of the original Framingham Study 
participants and their spouses who were first examined between 1971 and 1975, reexamined eight years later, 
and then every three to four years thereafter10. Children of the Offspring Cohort were recruited to form the 
Third Generation Cohort11. Subjects used in the current analyses were at least 16 years of age and were not taking 
medications to control lipid levels. Triglyceride concentrations were measured fluorometrically81 for all 9 exams 
of the Offspring Cohort, and exams 1 and 2 of the Third Generation Cohort. VLDL-cholesterol at exams 1–3 of 
the Offspring Cohort was determined by subtracting the bottom fraction cholesterol from total cholesterol81. 
Individual subject triglyceride values calculated as the average of the age- and sex-adjusted triglyceride concen-
trations over all available exams (i.e. the average of up to 9 exams for the Offspring Cohort, and up to 2 exams for 
Third Generation Cohort). VLDL-cholesterol was the average of up to three age- and sex-adjusted measurements.
Offspring-parent correlations (rOP) and regression slopes (βOP) were computed by assigning a weight 
of one-half to the offspring-father and one-half to the offspring-mother pair (if both parents were available), 
and assigning a weight of one to the offspring-parent pair if only one parent was available. Age and sex adjust-
ment was performed separately in the Offspring and Third Generation Cohorts using standard least-squares 
regression with the following independent variables: female (0,1), age, age2, female x age, and female x age2. 
Offspring-midparental correlations (rOM) and regression slopes (βOM) were computed by comparing each child’s 
age- and sex-adjusted value to the average of the age and sex-adjusted parental values in those families hav-
ing both parents. Full-sibling correlations (rFS) and regression slopes (βFS) were obtained by forming all ki(ki-1) 
sibpair combinations for the ki siblings in sibship i and assigning equal weight to each sibling82. The Lawrence 
Berkeley National Laboratory Human Subjects Committee approved use of the Framingham Cohort data for 
analysis.
Simultaneous quantile regression was performed using the sqreg command of Stata (version. 11, StataCorp, 
College Station, TX) and one thousand bootstrap samples were drawn to estimate the variance-covariance matrix 
for the 91 quantile regression coefficients between the 5th and 95th percentiles of the offsprings’ triglyceride dis-
tribution8,9. Post estimation procedures (test and lincom) were used to test linear combinations of the slopes with 
Σki -2 degrees of freedom for βOP and Σ (ki-1) degrees of freedom for βFS, where ki is the number of offspring in 
family i, and the summation is taken over all family sets. Quantile-specific expressivity was assessed by: 1) esti-
mating quantile-specific βOP ± SE and βFS ± SE for the 5th, 6th… 95th percentiles of the sample distribution using 
simultaneous quantile regression; 2) plotting the quantile-specific βOP and βFS coefficients vs. the quantile of the 
offsprings’ trait distribution; and 3) testing whether the resulting graphs was constant, or changed as a linear, 
quadratic, or cubic function of the percentile of the trait distribution using orthogonal polynomials. Heritability 
in the narrow sense (h2) was estimated as h2 = 2βOP/(1 + rspouse) from the offspring-parent regression slope (βOP), 
as h2 = βOM from the offspring-midparental regression slope (βOM), and as h2 = [(1 + 8rspouseβFS)0.5−1]/(2rspouse) 
from full-sibs regression slopes (βFS), where rspouse is the spouse correlation12.
Published reports of gene-treatment and gene-environment interactions were identified through PubMed 
and the citations within each paper retrieved. In many cases27–30,32,33,35,36,40,43,48,49,62,64,65,67,70, mean triglyceride con-
centrations had to be estimated from published figures using the formatting palette of Microsoft Powerpoint to 
extract their quantitative information (version 12.3.6 for Macintosh computers, Microsoft corporation, Redmond 
WA). Vertical lines were drawn showing the vertical distances between each plotted point and the X-axis, and 
overall height of the Y-axis, from which triglyceride concentrations were derived3.
Results
There were 3325 Third Generation subjects who had one or more parents in the Offspring Cohort (1089 had one 
parent, 2236 had both parents). There were 1016 sibships with two or more full siblings in the Offspring Cohort 
(532 with two, 302 with three, 122 with four, and 60 with ≥five full sibs) and 1171 sibships with two or more full 
siblings in the Third Generation Cohort (576 with two, 333 with three, 155 with four, and 107 with ≥five full sibs). 
Unadjusted average triglyceride (SD) for subjects used in the analyses was 2.390 (1.934) mmol/L in the Offspring 
Cohort and 1.279 (0.914) mmol/L in the Third Generation Cohort. In addition, sibships from the Offspring 
Cohort had an unadjusted average VLDL-cholesterol concentration of 0.585 (0.294) mmol/L for exams 1–3.
Correlational analyses showed spouses were concordantly related for age- and sex-adjusted triglycerides 
(rspouse = 0.15), log triglycerides (rspouse = 0.31), and VLDL-cholesterol (rspouse = 0.09). Table 1 presents the tra-
ditional least squares regression slopes between offspring and parent (βOP) and offspring and midparent (βOM) 
and among full sibs (βFS). Triglyceride heritability (h2 ± SE) was significant as traditionally estimated from 
βOP (0.146 ± 0.013), βOM (0.131 ± 0.012), or βFS (0.456 ± 0.031). Heritability was even stronger for log triglyc-
erides when estimated from βOP (0.360 ± 0.023), βOM (0.380 ± 0.023), or βFS (0.532 ± 0.030). Heritibility of 
VLDL-cholesterol was 0.343 ± 0.046 when estimated from full sibs (βOP unavailable because parents were not 
measured).
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Plasma triglyceride concentrations. Figure 1 (upper panel) presents the offspring-parent regression 
slopes (βOP) for selected quantiles of the offspring’s plasma triglyceride distribution with their associated her-
itability estimates (h2 the narrow sense). Heritability became progressively greater with increasing quantiles of 
the offspring’s distribution, and differed significantly between the 10th and 90th percentiles (P =  2.2 × 10−11). 
These selected quantile-specific heritability estimates were included with those of other quantiles to create the 
quantile-specific heritability function in the lower panel, i.e., where h2 (Y-axis) is plotted as a function of the 
quantile of the offspring’s sample distribution (X-axis). Specifically, the Y-axis represents heritability at the 5th 
quantile, the 6th quantile,…, and the 95th quantiles of the offspring’s distribution. The shaded area presents 
the 95% confidence intervals for the individual slopes at each quantile. The figure shows that h2 increased from 
0.033 ± 0.010 at their 10th percentile (P = 0.0009), 0.050 ± 0.016 at the 25th (P = 0.001), 0.111 ± 0.015 at the 
50th (P = 1.3 × 10−13), 0.230 ± 0.030 at the 75th (P = 1.7 × 10−14), and 0.428 ± 0.059 at the 90th percentile of the 
offspring’ distribution (P = 6.4 × 10−13). If the heritability was the same for all offspring quantiles as traditionally 
assumed, then the upper panel would display parallel regression lines, and the lower graph would present a simple 
horizontal line. In fact, the graph shows that heritability became progressively stronger with increasing quantiles 
of its offsprings’ triglyceride distribution, such that on average each 1-percent increase in the offspring distribu-
tion was associated with a 0.0047 ± 0.0007 increase in heritability (P = 2.9 × 10−14). Moreover, the increase in 
quantile-specific h2 with increasing offspring’s triglyceride concentrations was significantly nonlinear, exhibiting 
both quadratic (P = 1.7 × 10−6) and cubic (P = 0.0007) effects. With respect to individual quantiles, heritability 
was statistically significant (P < 0.003) at every percentile between the 5th and the 95th percentiles of the offspring’ 
distribution, and was 13-fold greater at the 90th than at the 10th percentile.
Full-sib quantile regression. Figure 2 shows that the full-sib regression slope for triglyceride concentra-
tions (βFS): 1) was 3.8-fold greater at the 90th (0.487 ± 0.081) than the 10th percentile (0.121 ± 0.010) of the sib dis-
tribution; and 2) increased 0.0042 ± 0.0007 (P = 1.8 × 10−9) for each percentile increase in the sibs’ distribution, 
and 3) exhibited significant nonlinearity (quadratic: P = 0.0007; cubic: P = 0.003). The full-sib slopes were sta-
tistically significant (P < 0.0001) at every percentile between the 5th and the 95th percentiles of the offspring’ dis-
tribution. Figure 2 also shows that siblings exhibited quantile-specific associations that were significantly greater 
at the 90th than 10th percentiles of the VLDL-cholesterol distribution (P = 0.04), and exhibited significant linear 
increases with each one-percent increment in their VLDL-cholesterol (0.0026 ± 0.0009, P = 0.003).
Log-transformed triglyceride concentrations. Quantile-dependent effects persisted when triglyceride 
concentrations were log transformed for offspring-parent (Fig. 3, P = 4.9 × 10−10) and full-sib regression slopes 
(Table 1, P = 0.007).
Replication. Significant quantile-specific increases in βFS were detected separately for fasting triglycerides 
measured in 2792 sibling in 1016 sibships in the Framingham Offspring Cohort (linear: P = 7.7 × 10−5; quadratic: 
P = 0.003; cubic: P = 0.003), and in 3384 sibling in 1171 sibships in the Framingham Third Generation Cohort 
(linear: P = 0.001; quadratic: P = 0.84; cubic: P = 0.55).
Discussion
Genome-wide association studies have identified 36 single nucleotide polymorphisms (SNP) associated with 
triglyceride concentrations5,6. The most significant SNPs are associated with the glucokinase regulator (GCKR, 
P = 2 × 10−239), apolipoprotein A1 (APOA1, P = 7 × 10−224), and lipoprotein lipase genes (LPL, P = 2 × 10−199). 
Because only about 11% of the triglyceride variance is explained by these 36 loci5,6, the current paper investigated 
Least-squares regression analysis Quantile regression analysis
Traditional regression slope
Increase in slope per 1% increase in the percentile of the 
dependent variable’s distribution Difference in slope between the 
90th and 10th percentilesLinear effect Nonlinear effects
Correl-ation Slope  ± SE Sig (P) Slope ± SE Linear (P) Quadratic (P) Cubic (P) Difference ± SE Sig (P)
Offspring Parent-
Triglycerides 0.18 0.0837 ± 0.0074 10−15 0.0027 ± 0.0004 2.9 × 10−14 1.7 × 10−6 0.0007 0.2269 ± 0.0339 2.2 × 10−11
Log triglycerides 0.25 0.2357 ± 0.0152 10−15 0.0023 ± 0.0004 4.9 × 10−10 0.65 0.11 0.1902 ± 0.0391 1.1 × 10−6
Offspring-Midparent
Triglycerides 0.22 0.1311 ± 0.0117 10−15 0.0035 ± 0.0006 6.5 × 10−9 0.004 0.08 0.2751 ± 0.0763 0.0003
Log triglycerides 0.32 0.3801 ± 0.0227 10−15 0.0030 ± 0.0007 1.3 × 10−5 0.46 0.65 0.2218 ± 0.0787 0.005
Full Sibling
Triglycerides 0.24 0.2434 ± 0.0154 10−15 0.0042 ± 0.0007 1.8 × 10−9 0.0007 0.003 0.3662 ± 0.0791 3.6 × 10−6
Log triglycerides 0.31 0.3096 ± 0.0151 10−15 0.0011 ± 0.0004 0.007 0.05 0.68 0.0747 ± 0.0360 0.04
VLDL-cholesterol 0.18 0.1767 ± 0.0231 2.2 × 10−14 0.0026 ± 0.0009 0.003 0.12 0.24 0.1974 ± 0.0945 0.04
Table 1. Traditional and quantile regression analyses of triglycerides and very low density lipoprotein (VLDL)-
cholesterol from the Offspring and Third Generation Framingham Cohorts. Triglycerides and log triglycerides: 
1174 offspring with one parent and 2507 with two parents, and 6176 full siblings in 2187 sibships; VLDL-
cholesterol: 2840 full siblings in 1029 sibships.
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heritability in the narrow sense (h2) as a more comprehensive, albeit less specific, estimate of genetic transmission. 
It showed that h2 increased significantly with increasing percentiles of the triglyceride distribution. This result 
was replicated for βFS in the Framingham Offspring Cohort and Framingham Third Generation cohort separately. 
This confirms our previous analyses of fasting plasma triglyceride concentrations vs. GRSTG2, and postprandial 
triglyceride concentrations vs. individual SNPs3. The current analyses also demonstrated quantile-dependency 
for VLDL-cholesterol concentrations in sibs. Quantile dependence was also significant for log-transformed tri-
glyceride concentrations. These analyses were based on simple robust estimates of heritability with nonparametric 
statistical significance determined from 1000 bootstrap samples.
Pharmacogenetics. Quantile-dependent expressivity predicts that genes affecting triglyceride con-
centrations should have a greater genetic effect prior to drug treatment when concentrations are high, than 
post-treatment when triglycerides are low. Moreover, smaller genotype differences when triglycerides concentra-
tions are reduced pharmacologically might appear as gene-drug interactions in the absence of any true biological 
interactions. This prediction was assessed in 14 published reports purporting gene-drug or gene-treatment inter-
actions on triglyceride response13–25.
For example, the histogram in Fig. 4A (insert) shows the reductions in fasting triglyceride levels reported by 
Lai et al. after three-week fenofibrate treatments15. The average decrease was significantly greater in APOA5 56 G 
carriers than non-carriers (35.8% vs. 27.9% decreases, P = 0.006). An accompanying editorial heralded its poten-
tial contribution to personalized medicine83. There is, however, an alternative interpretation of Lai et al.’s results 
from the perspective of quantile-dependent expressivity. Figure 4A shows that average triglyceride levels were 
higher before (1.58 ± 0.04 mmol/L) than after treatment (1.01 ± 0.02 mmol/L) and that triglyceride difference 
between genotypes were greater at the higher pre-treatment triglyceride levels (1.99–1.52 = 0.46 mmol/L differ-
ence, P = 0.01) than at the lower post-treatment triglyceride levels (1.06–1.00 = 0.06 mmol/L difference, P = 0.22), 
consistent with quantile-dependent expressivity. The smaller genetic effect size at the lower (post-treatment) than 
higher (pre-treatment) average triglyceride concentration requires that the trajectories of triglyceride reductions 
Figure 1. (upper panel) presents the offspring-parent regression slopes (βOP) for selected quantiles of the 
offsprings’ total triglyceride concentrations, with corresponding estimates of heritability (h2 = 2βOP/(1 + 
rspouse)). The slopes became progressively greater (i.e., steeper) with increasing quantiles of the triglyceride 
distribution. These quantile-specific regression slopes were included with those of other quantiles to create the 
quantile-specific heritability function in the lower panel. The statistical significance of the linear, quadratic and 
cubic trends and the 95% confidence intervals (shaded region) were determined by 1000 bootstrap samples. 
1 mg/dL = 0.01129 mmol/L.
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cannot move in parallel for different genotypes when triglycerides are decreased pharmacologically. Subtracting 
the pre-treatment from the post-treatment triglyceride levels will necessarily require a relatively greater triglyc-
eride decrease for the genotype with the higher pre-treatment triglyceride level vis-à-vis the genotype with the 
lower pre-treatment level.
Figure 2. Full-sib regression slopes (βFS) vs. quantiles of the sib’s triglyceride and VLDL-cholesterol 
distribution.
Figure 3. Offspring-parent regression slopes (βOP) vs. quantiles of the offsprings’ log-transformed triglyceride 
concentrations.
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Figure 4. Precision medicine perspective of different mean triglyceride reductions by genotypes following 
160 mg/d fenofibrate or fenofibrate/statin combination therapy (histogram inserts of mean changes by 
genotype) vs. quantile-dependent expressivity interpretation (larger pre-treatment genetic effect size when 
average triglycerides concentrations were high vs. lower, requiring nonparallel triglycerides reductions by 
genotype), for: (A) Lai et al.’s 2007 report of 87 APOA5 56 G carriers vs. 703 non-carriers (genotype difference 
in mean triglyceride reduction P = 0.006)15; (B) Cardona’s et al.’s 2009 report of 14 APOA5 -1131C carriers vs. 
22 non-carriers17; (C) Perez-Martinez et al.’s 2009 report of protected group (N = 236) consisting of the common 
allele homozygotes for GCKR rs780094C > T (CC), APOA5 −1131 T > C (TT), and APOA5 56 C > G (CC); 
an intermediate group (N = 490) consisting of homozygotes for GCKR rs780094C > T (CC) and carriers of the 
rare allele for either APOA5 −1131 T > C (CT or CC) or APOA5 56 C > G (CG or GG) or carriers of the rare 
allele for GCKR rs780094C > T (CT or TT) and homozygotes for both APOA5 −1131 T > C (TT) and APOA5 
56 C > G (CC); and a risk group (N = 118) consisting of carriers of the rare allele for GCKR rs780094C > T (CT 
or TT) and carriers of the rare allele for either APOA5 −1131 T > C (CT or CC) or APOA5 56 C > G (CG or 
GG) with triglycerides > 1.69 mmol/L at baseline16; (D) Brautbar et al.’s 2011 report on 47 GG, 256 GA and 371 
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Figures 4 and 5 display additional reports, initially interpreted from the perspective of personalized medicine, 
that are consistent with quantile-dependent expressivity, i.e., larger pre-treatment genetic effects when average 
triglycerides are high, followed by smaller post-treatment genetic effects when average triglyceride concentra-
tions are low. Cardona et al. reported that the triglyceride reduction from fenofibrate treatment was over twice 
as great in TC/CC genotypes than TT homozygotes of the APOA5 -1131T polymorphism (2.34 vs. 1.15 mmol/L 
decreases, Fig. 4B histogram)17. The graph show that there was a greater triglyceride difference between carri-
ers of the C-allele and TT homozygotes before treatment (5.80–3.74 = 2.06 mmol/L) when average triglycer-
ides were high (4.54 mmol/L) than after treatment (3.46–2.60 = 0.86 mmol/L) when average triglycerides were 
lower (2.93 mmol/L). Perez-Martinez et al16. identified three genetic risk groups in hypertriglyceridemic subjects 
(pre-treatment triglycerides >1.69 mmol/L) derived from the GCKR-APOA5 loci: a protected group, an interme-
diate group, and a risk group. The histogram in Fig. 4C shows the decreases in plasma triglyceride concentration 
differed significantly between these groups after three-week fenofibrate treatment (P = 0.003): greatest in the 
risk group, intermediate in the intermediate group, and least in the protected group. However, the cross-sectional 
genotype differences were greater at baseline (risk: 3.08; intermediate: 2.71; protected: 2.40 mmol/L, P = 0.009) 
when the average triglyceride concentration over all genotypes was high (2.68 mmol/L), than after treatment (all 
genotypes approximately the same, P = 0.20) when average triglycerides were low (1.57 mmol/L, estimated from 
their Fig. 316).
Brautbar et al. reported that three SNPs in the ZNF259-APOA5 gene region on chromosome 11 showed 
substantially smaller genotype differences on fenofibrate/statin combination treatment when average triglyc-
eride levels were low (1.64 mmol/L) compared to pretreatment differences when average levels were higher 
(3.15 mmol/L)14. Specifically, treatment reduced differences between GG, GA, and AA genotypes of rs3741298 
from 3.77, 3.20, and 3.04 (P = 3.2 × 10−5) to 1.67, 1.65, and 1.64, respectively (P = 0.79, Fig. 4D), between the CC, 
CG and GG genotypes of rs964184 from 3.51, 3.41, 3.01 mmol/L (P = 2.3 × 10−7) to 1.77, 1.71, and 1.61 mmol/L, 
respectively (P = 0.18, Fig. 4E), and between GG, GA, and AA genotypes of rs10750097 from 3.37, 3.26, and 
3.05 mmol/L (P = 0.002) to 1.62, 1.66, and 1.63 mmol/L, respectively (P = 0.86). Although the mean triglycer-
ide reductions by genotype did not differ significantly by genotype in Brautbar’s paper (0.25 ≤ P ≤ 0.82), one by 
Aslibekyan et al. did report that the rs964184 polymorphism affected fenofibrate-induced triglyceride change 
significantly (P < 0.001)13.
Irvin et al.18 (Fig. 4F) reported that fenofibrate-induced changes in plasma triglyceride concentrations dif-
fered significantly (P = 0.05) between APOE ε3ε3 homozygotes (−29.0%), ε4-carriers (−26.4%) and ε2-carriers 
(−34.4%), an expected result from quantile-dependent expressivity given that the triglyceride difference between 
ε3ε3, ε4-carriers, and ε2-carriers were greater before treatment (1.48, 1.60, 1.75 mmol/L, respectively, P = 0.02) 
when average triglycerides were high (1.54 ± 0.03 mmol/L) than after treatment (0.97, 1.04, 1.10 mmol/L, 
P = 0.09) when average triglycerides were low (1.00 ± 0.02 mmol/L).
The histogram in Fig. 5A shows substantially greater triglyceride reductions due to fenofibrate treatment in 
44 carriers of LPL P207L mutation than in 247 non-carriers who were hypertriglyceridemic (13.3 vs. 4.5 mmol/L 
average reductions). Brisson et al. attributed the difference to the mutation’s modulating effect on the fenofibrate 
response19. Alternatively, quantile-dependent expressivity would attribute the difference to the greater genetic 
effect size of the mutation (18.93–7.38 = 11.5 mmol/L difference) when average triglycerides were elevated before 
treatment (9.13 mmol/L) compared to post-treatment genetic effect size (5.60–2.88 = 2.72 mmol/L difference) 
when average triglycerides were much lower (3.29 mmol/L).
Several studies report statin-induced triglyceride reductions that were genotype specific. Pedro-Botet et al. 
reported that the average decrease in plasma triglyceride concentrations was significantly affected by APOE iso-
forms in a multicentric, double-blind clinical trial of 328 patients who received 10 mg/day of atorvastatin for 
one year20. The histogram in Fig. 5B shows that ε2-carriers had the greatest average decrease (0.64 mmol/L), 
ε4-carriers intermediate decrease (0.44 mmol/L), and ε3ε3 the smallest average decrease (0.34 mmol/L). However, 
the genetic effect size of the ε2-allele vis-à-vis ε3ε3 homozygotes was greater at baseline (0.46 ± 0.26 mmol/L) 
when average triglycerides were higher (1.94 mmol/L) than after one-year (0.16 ± 0.19 mmol/L) when average 
triglycerides concentrations were reduced (1.55 mmol/L), consistent with quantile-dependent expressivity.
These results agree with an earlier report by Carmena et al. of 94 patients with familial hypercholesterolemia 
(FH) who received 80 mg lovastatin for 80 days21. Figure 5C’s histogram shows that ε2-carriers showed the great-
est average decrease (−0.69 mmol/L), ε4-carriers intermediate decrease (−0.52 mmol/L), and ε3ε3 the smallest 
average decrease (−0.41 mmol/L). Again, the genetic effect size of the ε2-allele vis-à-vis ε3ε3 homozygotes was 
greater at baseline (0.39 ± 0.29 mmol/L difference) when average triglycerides were higher (1.70 ± 0.02 mmol/L) 
than after one-year of lovastatin treatment (0.12 ± 0.15 mmol/L difference) when average triglycerides concentra-
tions were reduced (1.23 ± 0.01 mmol/L), consistent with quantile-dependent expressivity.
Anagnostopoulou et al. reported significantly greater triglyceride reductions in carriers of the I-allele of the 
CEPT I405V polymorphism than VV homozygotes (0.70 vs. 0.47 mmol/L decreases, P = 0.04) from 10–40 mg/
day simvastatin (Fig. 5D)22. Average triglyceride concentrations decreased from 2.01 to 1.34 mmol/L, and accord-
ingly the genotype difference decreased from 0.27 mmol/L before treatment to 0.05 mmol/L after.
As a final example involving lipid-lowering drugs, Tuteja et al. reported that the C-allele of PDXDC1 
rs3198697 accentuated the decrease in triglycerides from niacin-statin combination therapy (P = 0.02, not 
AA genotypes of rs3741298 in the APOA5-ZNF259 gene region who were also statin treated14; (E) Brautbar 
et al.’s 2011 report on 27 CC, 202 CG and 445 GG genotypes of rs964184 in the APOA5-ZNF259 gene region 
who were also statin treated14; and (F) Irvin et al.’s 2010 report on 81 APOE ε2-carrier, 454 ε3ε3, and 203 ε4-
carriers18.
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Figure 5. Precision medicine perspective of mean changes in triglyceride concentrations by genotypes 
(histogram inserts) vs. quantile-dependent expressivity perspective of larger genetic effect size when average 
triglycerides concentrations were high vs. low requiring nonparallel changes in triglycerides by genotype, for: 
(A) Brisson et al.’s 2015 report on 160 mg/d fenofibrate therapy in 44 carriers of LPL P207L mutation vs. 247 
non-mutants19; (B) Pedro-Botet et al.’s report on 10 mg/day of atorvastatin’s effect in 10 male APOE ε2-carriers, 
111 male ε3ε3, and 74 male ε4-carriers20; (C) Carmena et al.’s 2012 report on 80 mg/d lovastatin’s effect on 7 
APOE ε2+, 58 ε3ε3, and 29 ε4+ familial hypercholesterolemia (FH) patients21; (D) Anagnostopoulou et al. 
2007 report of 10–40 mg/d simvastatin in 160 carriers of the I-allele and 20 VV homozygotes of the CEPT 
I405V polymorphism22; (E) Balakrishnan et al.’s 2002 report of 93 patients who received pancreas transplants by 
APOE isoforms24; (F) Cabello et al.’s 2018 report on the effect of bexarotene treatment on carriers of the APOA5 
-1131T > C or APOC3 388 T > C mutations vs. non-mutations25.
9Scientific RepoRtS |         (2020) 10:4486  | https://doi.org/10.1038/s41598-020-60965-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
displayed)23. Once again, a larger pre-treatment genetic effect size per dose of the C-allele (0.14 mmol/L per copy) 
occurred when average triglycerides were high (1.88 mmol/L), and smaller post-treatment effect size occurred 
(β = −0.04 mmol/L per copy) when average triglycerides were low (1.35 mmol/L).
A non-pharmacological example is provided by Balakrishnan et al. who reported that triglyceride concen-
trations were significantly reduced, from 1.87 to 1.50 mmol/L, in 93 patients who received pancreas transplants 
(P = 0.002)24. The triglyceride difference between APOE ε4-carriers and ε3ε3 homozygotes went from being sig-
nificant (0.45 mmol/L as estimated from their Fig. 2, P = 0.04) to nonsignificant (0.08 mmol/L) after the trans-
plant, consistent with quantile-dependent expressivity (Fig. 5E).
Hypertriglyceridemia is the most common reason for discontinuing bexarotene, a drug used for treating cuta-
neous T-cell lymphomas84. Cabello et al. proposed that carriers of the APOA5 -1131T > C or APOC3 c.40 C > G 
mutations were the best candidates for bexarotene treatment because of their smaller triglyceride response25. 
Figure 5F presents the triglyceride differences between genotypes before and after oral bexarotene therapy while 
receiving prophylactic hypolipidemic therapy and 50 μg/d of levothyroxine sodium. From the perspective of per-
sonalized medicine, carriers of either minor allele experienced smaller triglyceride increases than non-carriers 
(1.25 vs. 2.39 mmol/L), whereas quantile dependent-expressivity would ascribe some of the effect to the smaller 
genetic difference between carriers and non-carriers before treatment (effect size: + 0.12 mmol/L) when average 
triglyceride concentrations were lower (1.59 mmol/L) than after treatment (effect size: −1.01 mmol/L, P = 0.02) 
when average triglyceride concentrations were higher (3.53 mmol/L).
To summarize, whereas other papers advocate individualized drug prescriptions using genetic markers to 
target patients (e.g., the histograms of Figs. 4 and 5), quantile-dependent expressivity postulates that these genetic 
markers follow different trajectories due to smaller genetic effects at lower triglyceride concentrations. It is unnec-
essary to hypothesize pharmacologic interactions of these genetic markers with treatment, rather APOA5, GCKR, 
APOA1, and APOE are simply among the brightest genetic signals tracking the reduced heritability.
implications regarding gene-environment interactions. Environmental factors that distinguish 
higher vs. lower triglycerides (e.g., obesity, physical inactivity, smoking, alcohol, high-carbohydrate diets, T2DM) 
are predicted to produce different genetic estimates under quantile-dependent expressivity. Traditionally, these 
differences have been attributed to gene-environment interactions, where: 1) the effect of the genotype on the 
phenotype differs by environment26–37,41–43,45–55,58–63,65–67,74–80, or equivalently: 2) the effect of the environment on 
the phenotype differs by genotype36,38–40,44,56,57,59,64,68–72. In almost every case, these were explicitly interpreted as 
arising from a biological interaction between gene product and treatment. Not one of the cited reports consid-
ered the differences in average triglyceride levels between environmental conditions as an explanation of their 
observed results. As a causal model, quantile-dependent expressivity may arise from concentration-dependent 
effects of the mutations affecting triglyceride concentrations, e.g., impaired catabolism due to slower lipoprotein 
lipase activity having a greater effect when triglycerides were high than when low. Biologically, and from the 
perspective of chemical reactions, this makes more sense than the traditional fixed effect size. In our heritability 
analyses, it is possible that shared environmental effects contributed to offspring parent-regression slopes and that 
these too were quantile dependent. In contrast, our original GRSTG2 and the published examples to follow26–79, 
show quantile-dependent expressivity for genetic variants that are independent of shared environmental effects. 
The examples to follow represent interactions that are consistent with quantile-dependent expressivity because 
they show larger genetic effect sizes at higher average triglyceride concentrations.
Body mass index and waist circumference. Meta-analyses suggest that plasma triglyceride concentra-
tions decrease 0.015 mmol/L per kg of weight loss85. BMI and waist circumference are associated with higher tri-
glyceride concentrations due, at least in part, to the release of free fatty acids from visceral depots causing greater 
hepatic synthesis of VLDL86. Most reports of gene-weight interactions appear to be at least partially attributable 
to quantile-dependent expressivity, including six studies based on genetic risk scores (GRSTG)26–31. Cole et al. 
reported that the effect of their GRSTG on triglyceride concentrations was significantly larger in obese subjects 
(effect size ± SE: 0.480 ± 0.053 mmol/L for BMI ≥ 35 kg/m2) then in lean subjects (0.261 ± 0.034 mmol/L for BMI 
≤ 23 kg/m2), and intermediate in subjects with an intermediate BMI (0.354 ± 0.029 mmol/L)26. Ali et al. reported 
that each unit increment in their GRSTG was associated with a 2.4% triglyceride-increase in overweight/obese 
subjects, and a 1.5% triglyceride-increase in normal weight subjects27. Quantile-dependent expressivity would 
attribute these differences to the higher average triglyceride concentrations of the obese subjects reported by Cole 
et al. (>0.50 mmol/L higher) and the overweight/obese subjects reported by Ali et al. (estimated >0.40 mmol/L) 
than their lean comparison group.
Klimentidis et al.28. report that increasing tertiles of waist-to-hip ratio were associated with progressive 
increases in the GRSTG effect size (estimated β1st tertile = 0.16, β2nd = 0.18, and β3rd = 0.22, PInteraction = 3.9 × 10−8). 
This, however, was in the context of highly significant increases in average triglyceride concentrations with 
increasing waist circumference (P = 1.3 × 10−56). Zubair et al. reported that the triglyceride difference between 
a high and low GRSTG score was greater in overweight/obese women than leaner women (0.49 vs. 0.29 mmol/L, 
Pinteraction = 0.03) and greater in broad-waisted than slim-waisted women (0.54 vs. 0.27 mmol/L, Pinteraction = 0.02)29. 
Again, these differences are consistent with quantile-dependent expressivity given that average triglycerides 
concentrations were greater in overweight/obese than leaner women (1.38 vs. 1.22 mmol/L) and greater in 
broad-waisted than slim-waisted women (1.44 vs. 1.19 mmol/L, calculated from their published data).
Justesen et al. reported significant interactions between adiposity and their 39-SNP GRSTG in two Danish 
cohorts: the Inter99 cohort (N = 5961 subjects) and the Health2006 cohort (N = 2565 subjects)30. BMI was 
divided into normal weight, overweight, and obese. Waist circumferences were divided into normal, centrally 
overweight, and centrally obese. Both cohorts showed triglycerides that were significantly affected by BMI x 
GRSTG interactions (Inter99: P = 0.002; Health 2006: P = 0.02; combined; P = 9.8 × 10−5) and waist circumference 
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x GRSTG interactions (Inter99: P = 0.0001; Health 2006: P = 0.05; combined; P = 2.0 × 10−5), with a larger genetic 
effect among individuals who were obese. However, average triglyceride levels for normal weight, overweight, 
and obese increased from 0.92, to 1.23 to 1.55 mmol/L in the Inter99 cohort, respectively, and from 0.94 to 1.23 to 
1.54 mmol/L in the Health2006 cohort. Similarly, average triglyceride levels for normal, centrally overweight, and 
centrally obese subjects increased from 0.96 to 1.26 to 1.49 mmol/L in the Inter99 cohort and from 0.95 to 1.18 to 
1.41 mmol/L in the Health2006 cohort. From the perspective of quantile-dependent expressivity, greater adiposity 
was an indicator of higher average triglyceride concentrations and its larger genetic effect.
Ahmad et al. reported that each unit increase in their 40-SNP GRSTG produced a significantly stronger effect 
on triglycerides in overweight and obese (1.013% triglyceride increase) than healthy weight women (1.011%, 
Pinteraction = 0.004), and a significantly stronger effect in centrally overweight and obese (1.012%) than centrally 
healthy weight women (1.010%, Pinteraction = 0.005)31. These results are consistent with quantile-dependent expres-
sivity and the higher triglyceride concentrations of the overweight and obese vs. healthy weight women (1.8 vs. 
1.3 mmol/L, P < 0.0001), and the centrally overweight and obese vs. centrally normal weight women (1.7 vs. 
1.2 mmol/L, P < 0.0001).
Gene-weight interactions have also been reported for individual SNPs, including those associated with 
APOA526,32–34, LPL26,35–43, GCKR26,44, insulin receptor substrate-1 (IRS-1)45,46, methylenetetrahydrofolate reduc-
tase (MTHFR)47,48, proprotein convertase subtilisin/kexin type 9 (PCSK9)48, APOB49, APOE50, peroxisome 
proliferator-activated receptor γ 2 (PPARγ2)51, and patatin-like phospholipase domain-containing protein 3 gene 
(PNPLA3)52.
The APOA5 gene is the strongest genetic determinant of plasma triglyceride concentrations87. Four stud-
ies report interactions between BMI and APOA5 polymorphisms that are consistent with quantile-dependent 
expressivity. Wu et al. reported that the effect size for the Gly185Cys polymorphism at APOA5 rs3741297 was 
accentuated in Filipinos with a higher waist circumference32. Specifically, it increased from 0.13, 0.06, 0.30, to 
0.96 mmol/L from the first to the fourth quartiles of waist circumference in mothers (Pinteraction = 0.01), and from 
0.19, 0.03, 0.13, to 0.58 mmol/L from the first to the fourth quartiles in offspring (Pinteraction = 0.007). Average 
triglycerides levels also increased from the first to the fourth quartiles of waist circumference, i.e., 0.96, 1.24, 
1.38, 1.55 mmol/L in mothers, and 0.86, 0.90, 1.03, and 1.23 mmol/L in offspring. A second study, by Kim et al.33, 
reported that the triglyceride difference between C-carriers and TT homozygotes of the APOA5 -1131T > C poly-
morphism was greater in overweight vs. normal weight Koreans at baseline (0.31 vs. 0.10 mmol/L) and their 3-year 
follow-up (0.55 vs. 0.19 mmol/L), corresponding to the higher average triglycerides in overweight than normal 
weight Koreans at baseline (1.47 vs. 1.02 mmol/L) and follow-up (1.60 vs. 1.06 mmol/L, estimated from their 
published graphs). Hsu et al.’s reported that the effect of the C-allele of rs662799 on plasma triglyceride concentra-
tions was greater in obese than lean patients (0.473 vs. 0.142 mmol/L per C-allele) in accordance with their higher 
average triglyceride concentrations (1.51 ± 0.07 vs. 0.90 ± 0.02 mmol/L)34. The fourth study, by Cole et al.26., 
reported a significantly greater effect size for APOA5 rs964184 in obese than lean subjects (β = 0.159 ± 0.03 vs. 
0.140 ± 0.03 mmol/L per G allele, Pinteraction = 0.009) whose average triglycerides differed by >0.5 mmol/L.
The LPL enzyme hydrolyzes triglycerides, and it participates in hepatic triglyceride-rich lipoprotein (TRL) 
clearance via the LDL receptor-related protein1. Multiple studies suggest that purported interactions between 
LPL polymorphisms and BMI on triglycerides are consistent with quantile-dependent expressivity, in that greater 
adiposity is associated with higher average triglyceride concentrations. Fisher et al. first reported a significant 
interaction between LPL S291 and BMI on triglycerides (Pinteraction = 0.02)35. Compared to those with a BMI < 25, 
their Fig. 2 showed heavier men had a greater triglyceride difference between genotypes (heavier vs. leaner: 
0.42 vs. −0.17 mmol/L difference) corresponding to their higher average triglyceride (1.94 vs. 1.54 mmol/L) 
in the Northwich Park Heart Study II project35. The European Atherosclerosis Research Studies reported that 
S291-carriers had greater increases in plasma triglycerides with increasing BMI than non-carriers (P < 0.01)36. 
Correspondingly, the genotype differences and average triglyceride concentrations were −0.08 and 0.89 mmol/L 
in the lowest BMI tertile, respectively, 0.18 and 1.00 mmol/L in the intermediate BMI tertile, respectively, and 0.18 
and 1.13 mmol/L in the highest BMI tertile, respectively. Mailly et al. reported a marginally greater triglyceride 
difference for carriers vs. non-carriers of the N9 mutation in overweight men (0.53 ± 0.27 mmol/L difference) 
with higher average triglycerides (1.86 ± 0.05 mmol/L) than in leaner men (0.02 ± 0.26 mmol/L difference) with 
lower average triglycerides (1.51 ± 0.05 mmol/L)37, as did Gerdes et al. for the highest BMI tertile (0.25 mmol/L 
genotype difference) with higher average triglycerides (1.12 mmol/L) vis-à-vis leaner men (0.10 mmol/L genotype 
difference) with lower average triglycerides (0.93 mmol/L)36, although neither reached statistical significance.
Figure 6A presents Jemaa et al.’s findings for a 10 week restricted calorie diet by the LPL HindIII polymor-
phism38. From a precision medicine perspective, the histogram (insert) shows plasma triglyceride concentration 
decreased significantly more in H2H2 homozygotes than H1-carriers (0.27 vs. 0.04 mmol/L decreases, P = 0.03). 
Consistent with quantile-dependent expressivity, the difference between genotypes was greater at baseline than 
after weight loss (0.32 ± 0.13 vs. 0.09 ± 0.11 mmol/L) in accordance with the higher average triglycerides at base-
line (1.23 ± 0.07 vs. 1.08 ± 0.05 mmol/L). Again, the smaller genetic effect size at the lower (post-treatment) than 
higher (pre-treatment) triglyceride concentrations require that the effects of the genotypes do not move in par-
allel when triglycerides are decreased by weight loss. Subtracting the pre-treatment from the post-treatment tri-
glyceride levels will necessarily create a relatively greater triglyceride decrease for the genotype with the higher 
pre-treatment triglyceride level vis-à-vis the genotype with the lower pre-treatment level.
Figure 6B presents Yamasaki et al.’s results for a 3-month lifestyle weight loss intervention that reduced 
dietary calorie intake from 2066 ± 27 to 1691 ± 22 kcal/d, increased energy expenditure from 2100 ± 34 to 
2266 ± 36 kcal/d, and reduced BMI from 25.65 ± 0.18 to 24.75 ± 0.17 kg/m239. The intervention produced 
twice as much triglyceride decrease in CC than CT or TT genotypes of the APOA5 -1135T > C polymorphism. 
Quantile-dependent expressivity would attribute the difference to the smaller genotype differences after weight 
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Figure 6. Precision medicine perspective of different mean changes in triglyceride concentrations by genotypes 
(histogram inserts) vs. quantile-dependent expressivity perspective of larger genetic effect size when average 
triglycerides concentrations were high vs. low requiring nonparallel changes in triglycerides by genotype, for: 
(A) Jenaa et al.’s 1997 report on the triglyceride response to 10-week weight loss diet in 58 H2H2 homozygotes 
and 57 H1-carriers of the of the LPL Hind III polymorphism (P = 0.03)38, (B) Yamasaki et al.’s 2015 report 
on the effect of a 3 month weight loss intervention in 87 TT, 163 TC, and 43 CC genotypes of the APOA5 
-1131T > CT polymorphism39, (C) Pollin et al.’s 2011 reported on the effect of a one-year lifestyle intervention 
in 919 subjects by the GCKR rs1260326 P446L polymorphism44; (D) Ruaño et al.’s report on the effect of 
6-month exercise training in 53 homozygotes and 22 A-allele carriers of the APOA1 −75 G/A polymorphism57; 
(E) Lin et al.’s report on the effect of going from a 54% carbohydrate/31% fat diet to a 70% carbohydrate/15% fat 
diet on 36 TT and 20 C-carriers of the APOA5 -1131T > C polymorphism68; (F) Humphries et al.’s 1996 report 
on the triglyceride response to a high saturated fat (26% SFA, 10% MUFA, 2% PUFA) and high polyunsaturated 
fat diets (9% SFA, 6% MUFA, 23% PUFA) in 45 H + and 10 H- genotypes of the LPL Hindlll gene loci69.
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loss than before (CC vs. TT difference ± SE: 0.19 ± 0.12 after vs. 0.43 ± 0.19 mmol/L before) due to the lower 
average triglyceride concentrations after weight loss (1.27 ± 0.04 vs. 1.55 ± 0.05 mmol/L).
Data extracted from Vohl et al.’s Fig. 1 showed that triglycerides increased significantly with increasing adi-
posity in LPL HindIII H + homozygotes but not H- carriers as measured by BMI (slope ± SE: 0.137 ± 0.052 
vs. 0.020 ± 0.041 mmol/L per kg/m2), and visceral adipose tissue area (0.009 ± 0.003 vs. 0.001 ± 0.004 mmol/L 
per cm2)40. The difference between genotypes increased with increasing BMI (0.12 ± 0.07 mmol/L per kg/
m2, P = 0.08), and visceral area (0.008 ± 0.005 mmol/L per cm2, P = 0.10), and average triglycerides con-
centrations also increased with increasing BMI (0.069 ± 0.033 mmol/L per kg/m2, P = 0.04) and visceral area 
(0.006 ± 0.003 mmol/L per cm2, P = 0.02). In another study, Senti et al.’s data showed that women with higher 
waist-to-hip ratios had somewhat greater triglyceride difference between H- carriers and H+ homozygotes 
(0.255 mmol/L difference) than women with lower waist-to-hip ratios (0.194 mmol/L difference), which prob-
ably corresponds to their difference in average triglycerides concentrations (1.26 vs. 0.90 mmol/L, respectively, 
P < 0.001)41.
Huang et al. reported that the triglyceride difference between SS and SX/XX genotypes of the LPL S447X pol-
ymorphism was greater in centrally obese than nonobese twins (0.24 vs. 0.06 mmol/L differences, P = 0.16), cor-
responding to the greater average triglycerides in centrally obese than nonobese twins (1.39 vs. 0.99 mmol/L)42. 
Garenc et al.’s data showed that the triglyceride difference between homozygotes for the S477-allele and 
X477-carriers was greater in obese men (0.80 mmol/L difference, P = 0.002) and women (0.53 mmol/L difference, 
P = 0.01) than normal weight men (0.09 mmol/L difference) and women (0.15 mmol/L difference), which corre-
sponds with the higher average triglycerides of the obese men (2.02 mmol/L) and women (1.25 mmol/L) com-
pared to the normal weight men (1.15 mmol/L) and women (1.10 mmol/L)43. Cole et al.’s reported significantly 
greater effect size for LPL rs12678919 in obese than lean subjects (β = −0.148 ± 0.03 vs. −0.050 ± 0.03 mmol/L 
per G allele, Pinteraction = 0.0007) whose average triglycerides differed by > 0.5 mmol/L26.
The GCKR Pro446Leu polymorphism (rs1260326) affects triglyceride concentrations by increasing hepatic glu-
cokinase activity44. Pollin et al. reported that there was a significant interaction (P = 0.04) between the triglyceride 
response to lifestyle intervention and rs1260326, with the 446L (T)-allele showing enhanced triglyceride reduction 
(P = 0.04, Fig. 6C)44. Consistent with quantile-dependent expressivity, triglycerides increased more per T-allele 
at baseline when triglycerides averaged 1.84 mmol/L (β = 0.141 mmol/L, P = 1.8 × 10−9) than after weight loss 
intervention when estimated triglycerides averaged 1.57 mmol/L (β = 0.084 mmol/L). This agrees with Cole et al.’s 
report of a significantly greater effect size in obese than lean subjects (β = 0.093 ± 0.03 vs. 0.067 ± 0.02 mmol/L 
per T allele, Pinteraction = 0.03) whose average triglycerides differed by > 0.5 mmol/L26.
Clausen et al. reported that the IRS-1 G972R mutation and obesity interacted to significantly increase plasma 
triglyceride concentrations (Pinteraction = 0.04)45. The difference between the R-carriers and GG homozygotes was 
seven-fold greater in obese than lean subjects (0.70 ± 0.42 vs. 0.10 ± 0.09 mmol/L), which could be due to the 
higher average triglyceride concentrations of the obese subjects (1.46 ± 0.10 vs. 0.91 ± 0.02 mmol/L). Baroni 
et al. also reported that R-carriers showed a greater difference from GG homozygotes in obese subjects (2.11–
1.73 = 0.38 mmol/L difference) than lean subjects (1.72–1.78 = −0.06 mmol/L difference) corresponding to the 
higher average triglyceride concentrations of the obese vs. lean subjects (1.80 ± 0.10 vs. 1.73 ± 0.09 mmol/L)46.
Zhi et al. reported that differences between the CC, CT, and TT genotypes of the MTHFR C677T polymor-
phism were significantly greater (P = 0.02) in women with BMI > 24 kg/m2 (0.90, 0.99, 1.09 mmol/L, respectively) 
who had higher average triglycerides (1.00 mmol/L), than in leaner women (0.65, 0.71, 0.63 mmol/L, respectively) 
who had low triglycerides (0.67 mmol/L)47. Our analyses of Yin et al.’s data (their Fig. 3) showed significant dif-
ferences between obese and lean Chinese for the effects of the MTHFR C677T genotype (0.387 vs. 0.029 mmol/L 
per dose of the T allele, Pinteraction = 0.006) and PCSK9 E670G (AG-AA difference: 1.64 vs. −0.17 mmol/L, 
Pinteraction < 0.0001) consistent with the higher average triglycerides of the overweight/obese Chinese (1.74 vs. vs. 
1.21 mmol/L)48.
Other gene-environment interactions involving body weight also appear attributable to quantile-dependent 
effects. With respect to the APOB XbaI polymorphism, Turner et al.’s data showed the effect size per dose of 
the X+ allele became progressively greater when going from the lowest (−0.012 mmol/L), to the intermediate 
(0.035 mmol/L) to highest BMI tertile (0.053 mmol/L, Pinteraction = 0.015)49. The lowest BMI tertiles had low aver-
age triglycerides (estimated as 0.84 mmol/L), the intermediate BMI tertiles had intermediate average triglycerides 
(0.89 mmol/L) and the highest BMI tertile had the highest average triglycerides (1.01 mmol/L).
Jemaa et al. reported that triglyceride concentrations were significantly lower for APOE ε3ε3 homozygotes 
than ε2- or ε4-carriers only in Tunisians who had BMI ≥ 30 kg/m2 (and presumably higher triglycerides)50.
Becer et al. reported that triglyceride concentrations were more strongly related to the dose of the A-alleles 
of the PPARγ2 Pro12Ala polymorphism in obese (0.115 mmol/L per A allele, P = 0.05) than nonobese subjects 
(0.054 mmol/L per A allele, P = 0.52) which probably relates to the higher average triglyceride concentrations of 
the obese subjects (1.71 ± 0.03 vs. 1.16 ± 0.03 mmol/L)51.
Finally, Stojkovic et al. reported a significantly stronger trend (P = 0.01) from the GG, CG, to CC genotypes 
of the PNPLA3 rs738409 polymorphism in overweight (i.e., 1.39, 1.50, 1.57 mmol/L for BMI > 25) than normal 
weight subjects (from 1.26, 1.20, 1.20 mmol/L for BMI ≤ 25, Pinteraction = 0.003) consistent with the higher triglyc-
erides in the overweight than normal weight subjects (1.54 vs. 1.20 mmol/L)52.
Physical activity. Aerobic physical activity decreases triglyceride concentrations by facilitating triglyc-
eride hydrolysis and use by skeletal muscles88. Meta-analyses suggest that triglyceride concentrations average 
0.11 mmol/L less for those who walked ≥6000 vs. <2000 steps/day, and 0.23 mmol/L less for those who exercised 
at 50% of VO2max for three 30-minute sessions per week compared to less active subjects89. Our analyses of 
Senti et al.’s data53 showed that the each dose of the H+ allele of the LPL HindIII polymorphism was associ-
ated with a triglyceride increase of 0.148 mmol/L in the least active men (expending ≤291 kcal/d), 0.135 mmol/L 
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in men expending 292–525 kcal/d, and 0.105 mmol/L in the most active men (>525 kcal/d) in an apparent 
gene-environment interaction. However, average triglyceride concentrations decreased with increasing physical 
activity: from 1.432, 1.250, to 1.106 mmol/L, respectively, suggesting an effect size for the H+ allele consistent 
with quantile-dependent expressivity.
Pisciotta et al. reported that the −265 T/C polymorphism of the APOA2 gene had a greater effect on tri-
glyceride concentrations in sedentary men (TT, TC, CC: 2.12, 1.64, 1.24 mmol/L) than active men who cycled 
120–150 km/wk (1.35, 1.33, 1.09 mmol/L, respectively), consistent with the higher triglyceride-cholesterol con-
centrations of the sedentary men (1.74 ± 0.11 vs. 1.30 ± 0.08 mmol/L)54.
Tanisawa et al. reported that triglyceride concentrations increased with increasing tertiles of their GRSTG (1st: 
0.93 ± 0.06, 2nd: 1.41 ± 0.13, 3rd: 1.46 ± 0.14 mmol/L) in Japanese men with low cardiorespiratory fitness, but not 
in those with higher fitness (1st: 0.92 ± 0.07, 2nd: 0.77 ± 0.06, 3rd: 1.05 ± 0.08 mmol/L, Pinteraction = 0.03) as pre-
dicted by quantile-dependent expressivity given the higher average triglycerides of the low vs. high fitness groups 
(1.30 ± 0.07 vs. 0.93 ± 0.04 mmol/L)55.
A small training study by Hagberg et al. reported larger triglyceride decreases in the +/− and +/+ than −/− 
genotypes of the LPL Pvull polymorphism (−0.68 ± 0.28 vs. −0.35 ± 0.18 mmol/L)56. However, training reduced 
average triglyceride concentrations from 2.04 to 1.41 mmol/L, and quantile-dependent expressivity would there-
fore predict the larger genotype difference at baseline than follow-up (+/− and +/+ vs. −/− difference: 0.25 vs. 
−0.08 mmol/L, respectively), producing nonparallel triglyceride decreases by genotype.
Ruaño et al. reported that 6 months of supervised aerobic exercise training produced significantly greater 
percent reductions in triglyceride concentration in A-carriers of the APOA1 -75G > A polymorphism than in 
GG homozygotes (P = 0.05)57. Figure 6D shows that average triglyceride concentrations were lower after training 
than before (1.30 vs. 1.49 mmol/L) corresponding to smaller genotypic differences after training than before (0.38 
vs. 0.72 mmol/L).
Smoking. Smokers are insulin resistant and exhibit impaired lipid metabolism, including impaired triglyc-
eride clearance after a mixed meal90. Meta-analyses suggest that triglyceride concentrations of smokers average 
9.1% higher than nonsmokers, and show a dose-dependent relationship from light (10.7%), moderate (11.5%) to 
heavy smokers (18%)91. Quantile-dependent expressivity would predict greater genetic effects on triglycerides in 
smokers than nonsmokers because of the smokers’ higher triglyceride concentrations. Czerwinski et al. in fact 
reported that the heritability of plasma triglyceride concentrations was higher in smokers (h2 = 0.70, average 
triglycerides 1.68 ± 0.06) than nonsmokers (h2 = 0.42, average triglycerides 1.58 ± 0.03)58. With respect to indi-
vidual loci, smoking is reported to modify the effects on triglycerides of the upstream stimulatory factor 1 (USF1) 
gene polymorphism rs251683959, C242T polymorphism of the cytochrome b-245 alpha chain (CYBA) gene60, 
–482 C > T in the insulin-responsive element of APOC361, LPL HindIII53,62, and LPL rs26363.
There are several reports of LPL polymorphisms affecting the triglyceride response to smoking. Peacock et al. 
found larger differences between H+H+ homozygotes and H- carriers of the LPL– HindIII polymorphism 
in smokers than nonsmokers (sexes combined: 0.23 vs. 0.01 mmol/L difference, P < 0.02) consistent with the 
smokers’ higher average triglyceride concentrations (1.03 vs. 0.92 mmol/L)62. Senti et al. reported a significant 
difference between H+ H+ homozygotes and H- carriers of the LPL HindIII polymorphism in sedentary smok-
ers (0.53 ± 0.26 mmol/L, P = 0.04) but not nonsmokers (0.05 ± 0.14 mmol/L), again, consistent with the higher 
average triglycerides of the sedentary smokers (1.54 ± 0.12 vs. 1.39 ± 0.07 mmol/L)53. Pyun et al.’s data showed a 
greater difference between CC homozygotes and T-carriers for LPL rs271 in smokers (2.20–1.96 = 0.24 mmol/L) 
than nonsmokers (1.66–1.63 = 0.03 mmol/L, Pinteraction = 0.009) consistent with the smokers’ higher average tri-
glycerides (2.11 vs. 1.65 mmol/L)63.
Niemiec et al. reported that the USF1 rs2516839 polymorphism modified the triglyceride response to 
smoking, however, triglyceride differences between the CC, CT and TT genotypes were greater in smokers 
(2.27 ± 0.26, 1.80 ± 0.09, 1.53 ± 0.10 mmol/L, respectively) in accordance with their higher average triglycerides 
(1.79 ± 0.07 mmol/L) than in nonsmokers (1.49 ± 0.11, 1.46 ± 0.06, 1.57 ± 0.08, respectively) in accordance with 
their lower concentrations (1.51 ± 0.05 mmol/L)59. Ge et al. reported that the difference between the CC homozy-
gotes and carriers of the T-allele of CYBA C242T polymorphism was significant in smokers (0.17 mmol/L, 
P = 0.01) but not nonsmokers (0.04 mmol/L, P = 0.76), which quantile-dependent expressivity would partially 
attribute to the smokers higher average triglyceride concentrations (1.33 vs. 1.21 mmol/L)60. Waterworth et al. 
reported that the smoking-triglyceride relationship was modified by both APOC3 –482 C > T (Pinteraction = 0.009) 
and 3238 C > G polymorphisms (Pinteraction = 0.04)61. Specifically, smokers’ had higher average triglyceride concen-
trations than nonsmokers (1.74 vs. 1.59 mmol/L), and as predicted, a greater effect per dose of the –482T-allele 
(0.135 vs. −0.009 mmol/L) and per dose of the 3238G-allele (0.380 vs. 0.113 mmol/L, calculated from their table 
two) than nonsmokers61.
Smokers did not have higher triglycerides than nonsmokers in the 41,000 subjects of the Population 
Architecture Using Genomics and Epidemiology (PAGE) study (mean ±  SE: 1.476 ±  0.010 vs. 
1.486 ± 0.005 mmol/L)92. Consistent with quantile-dependent expressivity, their meta-analysis did not show any 
significant SNP by smoking interactions.
Diet. Each 1% isoenergetic replacement of carbohydrates with fat is expected to decrease plasma triglycer-
ide concentrations by an average of 0.021 mmol/L if saturated, 0.019 if monounsaturated, and 0.026 mmol/L 
if polyunsaturated93. Adherence to a Mediterranean diet decreases plasma triglyceride concentrations by an 
average of 0.069 mmol/L94. Quantile-dependent expressivity would predict larger genetic effects on low-fat 
high-carbohydrate diets than high-fat low-carbohydrate diets, and larger genetic effects on Western than 
Mediterranean diets, in accordance with the expected higher triglycerides of the former.
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Gomez-Delgado et al. reported that decreases in plasma triglyceride due to adopting a Mediterranean diet 
were significantly greater in 203 GG homozygotes of the tumor necrosis factor alpha gene (TNFA, rs1800629) 
than in 48 carriers of the A-allele, i.e. approximately 0.31 vs. 0.12 mmol/L, respectively (P = 0.005)64. However, 
plasma triglyceride concentrations averaged approximately 1.80 mmol/L at baseline and 1.52 mmol/L on the diet, 
and correspondingly, the differences between the GG and GA/AA genotypes were 0.38 vs. 0.19 mmol/L, respec-
tively. A quantile-dependent interpretation of these results is that the Mediterranean diet decreased plasma tri-
glyceride concentrations, which in turn produced a smaller difference between genotypes.
Pyun et al.’s data showed a greater triglyceride difference between CC homozygotes and T-carriers for LPL 
rs263 with increasing energy intake: 0.005 mmol/L difference for ≤1500 kcal/d, 0.14 mmol/L difference for 
1501–2000 kcal/d, 0.13 mmol/L for 2001–2500 kcal/d, and 0.20 mmol/L for > 2500 kcal/d, Pinteraction = 0.02) corre-
sponding to the increasing average triglycerides concentrations with energy intake (1.73, 1.78, 1.78, 1.84 mmol/L, 
respectively)63.
Garcia-Rios et al. reported significant interactions between plasma concentrations of n-6 polyunsaturated 
fatty acids and LPL rs238 (Pinteraction = 0.05) and LPL rs1059611 (Pinteraction = 0.04)65. Below median n-6 PUFA 
concentrations, the rs1059611 triglyceride difference between AA homozygotes and carriers of the G allele was 
0.33 mmol/L and the average triglyceride concentration across genotypes was 2.14 mmol/L. Above the median, 
the genotype difference was smaller (−0.09 mmol/L) in accordance with lower average triglyceride concentra-
tions (1.37 mmol/L), consistent with quantile-dependent expressivity. Nearly identical results were reported for 
rs238, which was in strong linkage disequilibrium with rs1059611.
Garcia-Rios et al. also reported a significant interaction between plasma saturated fatty acids concen-
trations and the circadian clock gene Period 2 (PER2) rs2304672 on plasma triglyceride concentrations 
(Pinteraction = 0.004)66. Above the median plasma SFA concentration of 30.9 mmol/L, plasma triglyceride concen-
trations differed significantly between the carriers of the G allele and CC homozygotes (2.61–1.98 =  0.63 mmol/L, 
P = 0.001) but not below the median (1.43–1.51 = −0.08 mmol/L), consistent with the higher average triglyceride 
concentrations in those with the high plasma SFA concentrations (2.06 ± 0.06 vs. 1.50 ± 0.06 mmol/L).
Samoan triglyceride concentrations were elevated (average 1.18 mmol/L) if they consumed a modern dietary 
pattern, intermediate for a transitional dietary pattern (average 0.96 mmol/L), and low for a neo-traditional diet 
(average 0.83 mmol/L)67. Correspondingly, the difference between CC homozygotes and carriers of the T allele of 
the insulin induced gene 2 (INSIG2) rs9308762 differed significantly on the modern diet (0.88 mmol/L), showed 
intermediate difference for transitional diet (0.33 mmol/L), and showed no significant difference (−0.10 mmol/L) 
on the neo-traditional diet (Pinteraction  = 0.04)67.
Figure 6E presents Lin et al.’s report of a two-fold greater triglyceride increase in C-carriers of the APOA5 
-1131T > C polymorphism vs. TT homozygotes in going from a 54% carbohydrate/31% fat diet to a 70% car-
bohydrate/15% fat diet68. Consistent with quantile-dependent expressivity, the genotype difference went from 
0.13 ± 0.10 to 0.22 ± 0.10 mmol/L while average triglycerides increased from 0.83 ± 0.08 to 0.94 ± 0.05 mmol/L.
Figure 6F displays the significantly greater triglyceride decreases in LPL Hindlll H- carriers than H+ homozy-
gotes when switching from a high saturated fat to a high polyunsaturated fat diet (0.35 vs. 0.10 mmol/L decreases, 
P = 0.05) reported by Humphries et al.69 However, the high polyunsaturated fat diet produced smaller differences 
between H- and H+ genotypes than the high saturated fat diet (0.31 vs. 0.56 mmol/L) in accordance with its lower 
average triglyceride concentrations (2.15 vs. 2.29 mmol/L).
Figure 7A presents Carvalho-Wells et al.’s finding that switching from a low-fat diet to a high-fat diet con-
taining 3.45 g/d DHA produced significantly greater triglyceride reductions in APOE ε3ε4 heterozygotes 
(−0.48 ± 0.11 mmol/L) than ε3ε3 homozygotes (−0.22 ± 0.06 mmol/L, Pinteraction = 0.03). Average triglyceride 
concentrations were higher on the low-fat than high-fat diet (1.43 vs. 1.08 mmol/L), and the difference between 
genotypes was correspondingly greater on the low-fat than the high fat diet (0.33 vs. 0.06 mmol/l difference)70.
Figure 7B presents Kang et al.’s report of significantly greater triglyceride increases from a refined rice diet 
in carriers of C-allele than TT homozygotes of the APOA5 -1131 T > C polymorphism (0.53 vs. −0.01 mmol/L, 
P = 0.02)71. Again, the difference between genotypes was greater after the diet than before (0.92 ± 0.04 vs. 
0.38 ± 0.03 mmol/L difference) when average triglycerides were higher (2.03 ± 0.02 vs. 1.75 ± 0.01 mmol/L).
Finally, Fig. 7C,D present Vallée Marcotte et al.’s report of a significantly different triglyceride responses to 
5 g/day of fish oil by the neurexophilin-1 (NXPH1) rs7806226 polymorphism (Pinteraction = 0.004) and V-MYB 
avian myeloblastosis viral oncogene homolog (MYB) rs11154794 polymorphism (P = 0.02)72. The histograms 
present the greater triglyceide reductions in homozygotes. The difference between genotypes was greater at 
baseline when average triglycerides concentrations were higher (1.21 ± 0.04 mmol/L) than after treatment 
when average concentrations were lower (1.02 ± 0.04 mmol/L) for both rs7806226 (AA-AC: 0.187 ± 0.07 vs. 
0.018 ± 0.08 mmol/L) and rs11154794 (TT-TC: 0.087 ± 0.111 vs. 0.014 ± 0.075 mmol/L), consistent with 
quantile-dependent expressivity.
Alcohol. Triglycerides increase an average of 0.11 mmol/L per 23 g/d of alcohol consumed, equivalent to 1 
large beer89. Although De Vries et al. study of 394,584 subjects revealed no gene-alcohol interactions attain-
ing genomewide significance73, there are several reports of larger genetic effects in drinkers than nondrinkers 
in accordance with their higher average triglyceride concentrations and quantile-dependent expressivity. These 
include those by Ruixing et al. for APOC3 3238 C > G (rs5128) genotypes in drinkers (CC/CG/GG: 0.97, 0.95, 
1.28 mmol/L, P < 0.001) vs. nondrinkers (CC/CG/GG: 0.91, 1.01, 0.93 mmol/L, P = 0.002)74, by Yin et al. for GG 
vs. A-carriers of the APOA5 457 G > A (rs3135507) polymorphism in drinkers (1.01 vs. 0.95) vs. nondrinkers 
(0.97 vs. 0.99 mmol/L, PInteraction < 0.001)75, by Pyun et al.’s between LPL rs263 GG homozygotes and A-carriers in 
drinkers (1.97–1.78 = 0.19 mmol/L) vs. nondrinkers (1.65–1.64 = 0.01 mmol/L, Pinteraction = 0.009)63, and by Zhou 
et al. for the cholesteryl ester transfer protein (CETP) TaqIB polymorphism (rs708272) in drinkers (B1B1/B1B2/
B2B2: 1.42, 1.01, 0.88 mmol/L, P = 0.02) than nondrinkers (0.94, 1.17, 0.99 mmol/L, respectively, P = 0.18)76. In 
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each case, average triglyceride concentrations were greater in drinkers than nondrinker (Ruixing and Yin et al.: 
1.09 ± 0.03 vs. 0.97 ± 0.03 mmol/L, P = 0.0174,75; Pyun et al.: estimated 1.90 vs. 1.65 mmol/L63; Zhou et al.: 
1.17 ± 0.09 vs. 1.04 ± 0.06 mmol/L76).
Tan et al. deduced a significant interaction between alcohol intake and the aldehyde dehydrogenase 2 gene 
(ALDH2) in their effect on triglyceride concentrations (P = 3.3 × 10−5)77. Specifically, the triglyceride difference 
between GG homozygotes and A carriers increased from nondrinkers (−0.09 mmol/L), to drinkers consuming 
1–10 g/d (0.15 mmol/L), 10–30 g/d (0.26 mmol/L), to ≥30 g/d (0.51 mmol/L). However, average triglyceride con-
centrations also increased from nondrinkers (1.21 mmol/L), 1–10 g/d (1.21 mmol/L), 10–30 g/d (1.42 mmol/L), 
to ≥30 g/d (1.48 mmol/L) in support of a quantile-dependent expressivity.
insulin resistance. VLDL overproduction due to diminished degradation of newly synthesized apo B, 
increased free fatty acid flux to the liver, and increased de novo hepatic lipogenesis all contribute to hypertri-
glyceridemia in T2DM86. Klimentidis et al.28 reported that the effect of GRSTG on triglyceride concentrations 
increased progressively with increasing tertiles of fasting insulin (estimated β = 0.15, β  = 0.21, β  = 0.23, 
P = 2.7 × 10−11) and HOMA-IR (estimated β = 0.14, β = 0.21, β  = 0.24, P = 2.5 × 10−11), in the context of a 
highly significant triglyceride increases with both (fasting insulin: P = 2.4 × 10−100; HOMA-IR: P = 9.1 × 10−133). 
Justesen et al. also reported that higher HOMA-IR was associated with a greater affect of GRSTG on triglycerides 
concentration (Pinteraction = 0.0009), presumably in association with rising average triglyceride concentrations, 
although the triglyceride-HOMA-IR relationship was not reported30.
Figure 7. Precision medicine perspective of different mean changes in triglyceride concentrations by genotypes 
(histogram inserts) vs. quantile-dependent expressivity perspective of larger genetic effect size when average 
triglycerides concentrations were high vs. low requiring nonparallel changes in triglycerides by genotype, for: 
(A) Carvalho-Wells et al.’s 2012 report on the triglyceride response to switching from a low-fat (24% fat, 59% 
carbohydrate) to high-fat diet (38% fat, 45% carbohydrate with 3.45 g DHA/d) in 44 APOE ε3ε3 homozygotes 
vs. 44 ε3ε4 heterozygotes (Pinteraction = 0.03)70; (B) Kang et al.’s 2014 report of switching from their usual to a 
refined rice diet in 43 TT homozygotes and 50 C carriers of the APOA5 -1131 T > C polymorphism71. (C) Vallée 
Marcotte et al.’s 2016 report on starting omega-3 (n-3) fatty acid supplementation in 142 AA homozygotes 
and 66 AC heterozygotes of the neurexophilin-1 (NXPH1) rs7806226 polymorphism72; (D) Vallée Marcotte 
et al.’s 2016 report on starting omega-3 (n-3) fatty acid supplementation in 155 TT homozygotes and 53 CT 
heterozygotes of the V-MYB avian myeloblastosis viral oncogene homolog (MYB) rs1115479472.
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Inamdar et al. reported that T2DM patients, who had higher average triglycerides than non-T2DM patients 
(1.90 vs. 1.27 mmol/L), showed greater carrier-noncarrier triglyceride differences for APOE ε2 (0.56 vs. 0.31) 
and ε4 (−0.45 vs. −0.12 mmol/L)78. Data presented by Vohl et al. showed that the fasting triglyceride difference 
between LPL-HindIII H + H + homozygotes and H-carriers were greater for fasting insulin concentrations 
≥71.5 than  < 71.5 pmol/L (0.65 vs. −0.12 mmol/L), consistent with the higher triglyceride concentrations of the 
former (2.01 vs. 1.18 mmol/L)40.
Pregnancy. There is a two-fold increase in circulating triglyceride levels during the third trimester due to 
enhanced VLDL-production and LPL supression86. Ma et al. reported that the effect of LPL deficiency had a 
much greater effect during pregnancy, when triglycerides are normally two- to three-fold higher, than when not 
pregnant, i.e., the LPL deficient women’s triglyceride were 20.2–22.5 mmol/L when pregnant vs. 3.4 mmol/L when 
not79.
Twin studies. Higher average triglyceride concentrations in MZ vs. DZ twins (1.33 vs. 1.07 mmol/L) could 
have contributed to the higher triglyceride correlations (rMZ = 0.527 vs. rDZ = 0.349) reported by Jermendy et al., 
affecting their estimation of genetic and environmental influences80.
Limitations. An important limitation of the analysis of the Framingham data its reliance on the simple for-
mula h2 = 2βOP/(1 + rspouse) and h2 =  [(1 + 8rspouseβFS)0.5 − 1]/(2rspouse) to estimate heritability12. These formula are 
unlikely to embody the true complexity of triglyceride inheritance. With respect to the published examples cited, 
we wish to emphasize that consistency with quantile-dependent expressivity does not disprove gene-environment 
interactions, rather, it provides an alternative interpretation. The examples presented are those originally inter-
preted from the perspective of precision medicine and biological interactions that might be more easily explained 
by quantile-dependent expressivity. It is not our contention that all triglyceride gene-environment interactions 
are explained by quantile-dependent expressivity. For example, Wojczynski et al.’s report of the significant effect 
(P < 0.0001) of the APOB rs676210 variant on the triglyceride response to fenofibrate would not be attributable to 
the quantile-dependent expressivity of Fig. 1 due to their being larger genotype differences post-treatment when 
triglycerides were low than pretreatment when triglycerides were high95. Some gene-environmental interactions 
may arise because triglycerides and environmental factors may be coregulated by shared genes or genes in strong 
linkage equilibrium. For that reason, the examples presented in Figs. 4–7 may be particularly informative for 
testing whether the genetic effect size is affected by average triglyceride concentrations because they represent 
intervention affecting triglyceride concentrations directly. Among the various genetic variants discovered to date, 
the proportion of the total triglyceride heritability explained by any specific SNP is too small to noticeably affect 
h25,6. Thus quantile-dependence of triglyceride heritability estimated from parent and offspring phenotypes does 
not necessarily describe the interactions between any particular genetic variant and its environment. Many pub-
lished reports do not provide the information required to evaluate their consistency with quantile-dependent 
expressivity, namely unadjusted triglyceride concentrations by genotype and condition.
In conclusion, assuming Falconer and Mackay’s formula apply12, these analyses suggest that triglyceride her-
itability is strongly dependent upon whether an individual is high or low relative to the triglyceride distribu-
tion in the population. Alternatively, quantile-dependent shared environmental effects could also give rise to 
the increase in βOP and βFS with increasing average triglyceride concentrations, however our previous findings 
showing increasing genetic effect size for GRSTG2 and during post-prandial triglyceride increases3, and the studies 
cited herein13–79 support a genetic interpretation. Quantile-dependent expressivity potentially provides a com-
mon principle underlying a plethora of published gene-drug and gene-environment interactions. Specifically, 
rather than attributing these interactions on the basis of triglyceride metabolism, gene functionality, and the 
specific metabolic effect of adiposity, physical activity, insulin resistance, diet, smoking, alcohol, and pregnancy, 
quantile-dependent expressivity postulates that the impaired functionalities of these genetic variants are simply 
triglyceride concentration dependent.
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